Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLOMIPHENE CITRATE vs OSPEMIFENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.
Ospemifene is a selective estrogen receptor modulator (SERM) that acts as an agonist on estrogen receptors in vaginal tissues, leading to proliferation and maturation of vaginal epithelium, while exhibiting antagonist activity on breast and endometrial tissues.
Treatment of ovulatory dysfunction in women desiring pregnancy,Off-label: male infertility (oligospermia), induction of ovulation in assisted reproductive technology
Treatment of moderate to severe dyspareunia (painful intercourse) due to vulvar and vaginal atrophy associated with menopause
50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.
60 mg orally once daily.
Terminal elimination half-life is approximately 5–7 days (120–168 hours) for the active zu-isomer, with a longer half-life for its metabolites. This prolonged half-life leads to accumulation with repeated dosing and sustained clinical effects.
Terminal elimination half-life is approximately 26 hours (range 20–30 hours), supporting once-daily dosing.
Hepatic metabolism; excreted in feces; active metabolites (possibly enterohepatic recirculation).
Primarily metabolized via CYP3A4 and CYP2C9, with minor contributions from CYP2C19, CYP2C8, and CYP2B6. Undergoes glucuronidation and sulfation.
Primarily fecal (approximately 50%), with about 8% renal excretion of unchanged drug and metabolites. Biliary excretion is significant, with enterohepatic recirculation contributing to prolonged elimination.
Primarily hepatic metabolism with biliary excretion; < 30% renal elimination as metabolites. Fecal excretion accounts for approximately 70% of total clearance.
Approximately 80–90% bound to albumin, with significant binding to other plasma proteins including sex hormone-binding globulin (SHBG).
> 99% bound to serum proteins, primarily albumin.
Apparent volume of distribution is large, approximately 50–100 L/kg, indicating extensive tissue distribution and accumulation, particularly in the liver and reproductive organs.
Approximately 4.2 L/kg, indicating extensive tissue distribution.
Oral: ~100% absorbed, but bioavailability is difficult to quantify due to extensive first-pass metabolism and enterohepatic cycling; essentially complete systemic exposure after oral administration.
Oral bioavailability is approximately 20–30% due to first-pass metabolism.
No specific dose adjustment guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not studied in severe renal impairment (Cr Cl <15 m L/min) or dialysis.
Contraindicated in patients with liver disease or hepatic dysfunction; no Child-Pugh based adjustments available.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). No dose adjustment for Child-Pugh Class A or B; use with caution.
Not recommended for use in children; safety and efficacy not established.
Not indicated for pediatric use; safety and efficacy not established.
Not indicated for use in elderly patients; no specific dosing recommendations.
No specific dose adjustment required; pharmacokinetics similar to younger adults. Monitor for vulvovaginal atrophy and thromboembolic risks.
Should not be used in patients with liver disease or abnormal uterine bleeding of undetermined origin.
There is an increased risk of endometrial cancer in women with an intact uterus. Use only when necessary and consider periodic endometrial evaluation.
Ovarian enlargement/cysts; visual disturbances; multiple pregnancy; ovarian hyperstimulation syndrome; vasomotor symptoms; blurred vision; prolonged use may increase risk of borderline or invasive ovarian tumors.
Endometrial cancer risk,Cardiovascular and cerebrovascular events (not evaluated in long-term studies),Venous thromboembolism (potential risk),Breast cancer (long-term safety not established),Use with caution in patients with hepatic impairment
Pregnancy; liver disease or history; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement due to polycystic ovary syndrome; hypersensitivity to clomiphene.
Undiagnosed abnormal genital bleeding,Known or suspected estrogen-sensitive cancer (e.g., breast cancer),Active or history of venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism),Pregnancy or women who may become pregnant
No significant food interactions. Avoid excessive alcohol consumption as it may impair fertility.
Take with food to minimize GI side effects. No specific food restrictions; however, avoid grapefruit juice as it may increase drug levels via CYP3A4 inhibition.
FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and third trimester: no data due to contraindication. Risk of multiple gestation (5-12%) increases risks of preterm labor, low birth weight, and congenital anomalies.
Ospemifene is contraindicated in pregnancy due to potential fetal harm. In animal studies, it caused fetal malformations (e.g., skeletal abnormalities) and embryo-fetal loss. There are no adequate human data; however, based on its estrogenic and antiestrogenic activity, it may interfere with fetal development. Use is not recommended at any trimester.
Excreted into breast milk; M/P ratio unknown. Clomiphene may reduce milk production due to anti-estrogenic effects. Because of potential for adverse reactions in nursing infants, women are advised not to breastfeed during treatment.
It is unknown whether ospemifene is excreted in human breast milk. No M/P ratio is available. Due to potential serious adverse effects in the nursing infant, breastfeeding is not recommended during treatment and for one week after the last dose.
No dose adjustments in pregnancy as drug is contraindicated. If pregnancy occurs, discontinue immediately. No pharmacokinetic studies in pregnant women; drug should not be used.
Ospemifene is contraindicated in pregnancy; therefore, no dosing adjustments are recommended. If pregnancy occurs, therapy should be discontinued. Due to lack of data and potential harm, no alternative dosing during pregnancy is advised.
Monitor ovarian size and estradiol levels to reduce risk of ovarian hyperstimulation syndrome (OHSS). Use only in patients with ovulatory dysfunction; rule out pregnancy before each cycle. Limit to 6 treatment cycles due to increased risk of ovarian cancer with prolonged use.
Ospemifene is a selective estrogen receptor modulator (SERM) indicated for moderate to severe dyspareunia due to vulvar and vaginal atrophy (VVA) in postmenopausal women. It has estrogenic effects on vaginal tissue but antiestrogenic effects on breast and endometrium. Monitor for thromboembolic events; contraindicated in history of VTE or PE. Not for use in women with breast cancer or estrogen-dependent neoplasia. May cause hot flashes and vaginal discharge.
Take clomiphene citrate exactly as prescribed, typically for 5 days starting on day 3-5 of menstrual cycle.,Ovulation usually occurs 5-10 days after the last dose; have intercourse every other day during this window.,Common side effects include hot flashes, mood swings, and visual disturbances; report persistent visual changes immediately.,Risk of multiple pregnancy (mainly twins) is increased; discuss with healthcare provider.,Avoid use if pregnant, have liver disease, or have abnormal vaginal bleeding.
Take one 60 mg tablet daily with food to reduce gastrointestinal upset.,Notify your healthcare provider if you experience unusual vaginal bleeding, breast pain, or lumps.,Seek immediate medical attention for signs of blood clots: chest pain, shortness of breath, leg swelling or pain, sudden severe headache.,Do not use if you have a history of blood clots, breast cancer, or liver disease.,Ospemifene is for non-surgical women postmenopausal; it does not prevent pregnancy or sexually transmitted infections.,Avoid smoking and limit alcohol intake to reduce the risk of blood clots.
No interactions on record
"Ospemifene, a selective estrogen receptor modulator, inhibits the metabolism of thiotepa, an alkylating agent, by competitively inhibiting cytochrome P450 (CYP) 2B6 and potentially other CYP enzymes involved in thiotepa's biotransformation. This leads to increased systemic exposure to thiotepa, elevating the risk of dose-dependent toxicities such as severe myelosuppression (e.g., neutropenia, thrombocytopenia) and mucositis. Clinically, coadministration may require significant thiotepa dose reduction to avoid excessive bone marrow suppression."
"Ospemifene is primarily metabolized by CYP3A4, and thioridazine is a moderate inhibitor of CYP3A4. Coadministration reduces ospemifene clearance, leading to elevated ospemifene serum concentrations, which may increase the risk of dose-dependent adverse effects such as thromboembolic events, hot flashes, and vaginal discharge. This interaction is clinically significant as it may exacerbate the endocrine and cardiovascular side effects of ospemifene."
"Ospemifene, a selective estrogen receptor modulator (SERM), is primarily metabolized by the cytochrome P450 enzyme CYP3A4. Clarithromycin is a potent macrolide antibiotic and a strong inhibitor of CYP3A4. Coadministration of clarithromycin with ospemifene significantly reduces the metabolic clearance of clarithromycin, leading to increased plasma concentrations of clarithromycin. This elevation can potentiate clarithromycin's adverse effects, including QT interval prolongation, cardiac arrhythmias, hepatotoxicity, and gastrointestinal disturbances, particularly in patients with preexisting risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLOMIPHENE CITRATE vs OSPEMIFENE, answered by our medical review team.
CLOMIPHENE CITRATE is a Selective Estrogen Receptor Modulator (SERM) that works by Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.. OSPEMIFENE is a Selective Estrogen Receptor Modulator (SERM) that works by Ospemifene is a selective estrogen receptor modulator (SERM) that acts as an agonist on estrogen receptors in vaginal tissues, leading to proliferation and maturation of vaginal epithelium, while exhibiting antagonist activity on breast and endometrial tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLOMIPHENE CITRATE and OSPEMIFENE depend on the specific clinical indication. These are both Selective Estrogen Receptor Modulator (SERM) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLOMIPHENE CITRATE is: 50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.. The standard adult dose of OSPEMIFENE is: 60 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLOMIPHENE CITRATE and OSPEMIFENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLOMIPHENE CITRATE is classified as Category A/B. FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and. OSPEMIFENE is classified as Category C. Ospemifene is contraindicated in pregnancy due to potential fetal harm. In animal studies, it caused fetal malformations (e.g., skeletal abnormalities) and embryo-fetal loss. There. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.